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Phosphorylation regulates transcriptional activity of
PAX3/FKHR and reveals novel therapeutic possibilities
Abstract
Inhibition of constitutive active signaling pathways, which are a characteristic phenomenon for many
tumors, can be an effective therapeutic strategy. In contrast, oncogenic transcription factors, often
activated by mutational events, are in general less amenable to small-molecule inhibition despite their
obvious importance as therapeutic targets. One example of this is alveolar rhabdomyosarcoma (aRMS),
in which specific translocations lead to the formation of the chimeric transcription factor PAX3/FKHR.
Here, we found unexpectedly that the transcriptional activity of PAX3/FKHR can be inhibited by the
kinase inhibitor PKC412. This occurs via specific phosphorylation sites in the PAX3 domain,
phosphorylation of which is required for efficient DNA-binding and subsequent transcriptional activity.
Consequently, we show that PKC412 exerts a potent antitumorigenic potential for aRMS treatment both
in vitro and in vivo. Our study suggests that posttranscriptional modifications of oncogenic transcription
factors can be explored as a promising avenue for targeted cancer therapy.
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Abstract 
Inhibition of constitutive active signalling pathways which are a characteristic phenomenon for many 
tumors, can be an effective therapeutic strategy. In contrast, oncogenic transcription factors, often 
activated by mutational events, are in general less amenable to small molecule inhibition, despite their 
obvious importance as therapeutic targets. One example of this is alveolar rhabdomyosarcoma (aRMS), in 
which specific translocations lead to the formation of the chimaeric transcription factor PAX3/FKHR. Here, 
we found unexpectedly that the transcriptional activity of PAX3/FKHR can be inhibited by the kinase 
inhibitor PKC412. This occurs via specific phosphorylation sites in the PAX3 domain, phosphorylation of 
which is required for efficient DNA-binding and subsequent transcriptional activity. Consequently, we show 
that PKC412 exerts a potent anti-tumorigenic potential for aRMS treatment both in vitro and in vivo. Our 
study suggests that post-transcriptional modifications of oncogenic transcription factors can be explored 
as a promising avenue for targeted cancer therapy.  
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Introduction 
 Inhibition of aberrant signaling can inhibit tumor growth, and since the success of Gleevec as targeted 
therapy for chronic myeloid leukemia, the principle of specific targeting of aberrant signal transduction 
pathways by small molecule inhibitors is thought to be a promising method to fight cancer (1) (2). This 
approach seems especially suitable for tumors with aberrations in upstream components of signaling 
cascades, cell surface receptors, or cytoplasmic kinases. So far, it has not been applied to tumors 
containing aberrations located at the end of signaling cascades, such as transcription factors (TF), for 
which fewer, if any, specific small molecule inhibitors are available. However, as TF represent the second 
most frequently mutated class of proteins in tumors (3), the availability of specific inhibitory compounds 
against this class of proteins would broaden the principle of targeted therapy to many additional tumor 
types.   
Rhabdomyosarcoma (RMS) accounts for 5 – 8 % of all pediatric malignancies and is the most common 
soft tissue sarcoma diagnosed in children (4). No targeted drug therapy is available for this tumor so far. 
Histopathologically, RMS is subclassified into two major forms, alveolar RMS (aRMS) and embryonal 
RMS (eRMS). 80% of the aRMS are characterised by specific translocations, involving the N-terminal part 
of PAX3 or PAX7, which in the majority of cases is fused to the C-terminal part of FKHR generating 
chimaeric transcription factors PAX3(or7)/FKHR. Overexpression of these translocation products is 
associated with a poor prognosis (5). Hence, the 5-year survival rate of aRMS patients is much lower 
compared to eRMS patients (6), and once metastasizing, aRMS become resistant to conventional chemo- 
and radiotherapy. Therefore, new therapeutic agents are urgently needed. 
Survival of translocation-positive aRMS cells is dependent on continuous expression of the fusion protein, 
as both downregulation (7) (8) or inhibition by competition (9) of PAX3/FKHR induces apoptosis in aRMS 
cells. However, the technical complexity of their application in vivo prevents a clinical implementation of 
such methods up to now. Therefore, identification of other, clinically applicable, mechanisms for PAX3-
FKHR inhibition would be of great interest.  
In this study, we present evidence for a mechanism allowing regulation of PAX3/FKHR activity by the 
kinase inhibitor PKC412 (10). PKC412 is an inhibitor of several kinases including PKC, Akt/PKB, c-Kit, 
FLT3, and FGFR, and is being evaluated in phase II clinical trials for AML patients (11). As we show here, 
the drug can influence the phosphorylation status of PAX3/FKHR and hence its transcriptional activity. 
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Furthermore, we demonstrate a potent antitumorigenic potential of PKC412 for aRMS in vitro and in vivo. 
These studies suggest that controlling the activity of oncogenic TFs by small molecule inhibitors is a 
promising therapeutic strategy against cancer. 
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Materials and Methods 
Cell lines and pharmacological inhibitors 
Two aRMS cell lines (Rh4, Rh30) and two eRMS cell lines (RD, Ruch-2) were used. The Rh4 cell line was 
obtained from the St. Jude Children’s Hospital, Memphis, USA. The Rh30 and RD cell lines were 
purchased from ATCC (Rockville, MD, USA). The RUCH-2 cell line was established in our laboratories 
(12). For ectopic expression studies of PAX3/FKHR 293T and NIH3T3 cells were used (ATCC).  
PKI166, CGP59326, NVP-ABG424-NX-4 and PKC412 were provided by Novartis (Basel, Switzerland), 
rapamycin was purchased from Sigma (Buchs, Switzerland). 
 
MTT Assay 
24 hours after seeding in 96-well plates (10’000 cells / well) cells were treated with pharmacological 
inhibitors in a volume of 100 µl medium including 10% serum for 96 hours. MTT assays (Roche, Rotkreuz, 
Switzerland) were then performed according to the manufacturer’s protocol.  
 
Trypan Blue Exclusion assay 
106 cells were seeded in 10 cm dishes and 24 hours later incubated with pharmacological inhibitors for 96 
hours. Floating and adherent cells were then pooled, spun down and resuspended in a defined volume of 
medium. After diluting the cells 1:1 with 0.4 % of trypan blue solution (Sigma), alive and dead cells were 
counted. 
 
Caspase-3 assay 
Active caspase-3 was detected by the CaspGLOW red active caspase-3 staining kit (Biovision, USA) 
according to the manufacturer’s instructions. Briefly, 3 x 105 cells per 6-well were treated with 0.5 µM 
PKC412 for 24 - 72 hours, then floating and trypsinized cells were pooled, spun down, and incubated with 
Red-DEVD-FMK caspase-3 inhibitor for 45 min at 37°C. Cells positive for active caspase-3 were scored 
by fluorescence microscopy.  
 
Immunoblotting 
Immunoblotting was performed as described previously (13) using primary antibodies against PARP (Cell 
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Signaling Technology, Danvers, USA; 1:1000), FKHR (C20, Santa Cruz Biotechnology, Heidelberg, 
Germany; 1:500), PCNA (BD Transduction Laboratories, San Jose, CA, USA; 1:1000), Actin (A2103, 
Sigma; 1:1000) and tetra His (Qiagen, Hombrechtikon, Switzerland; 1:1000).  
 
Immunofluorescence 
Immunofluorescence of cells plated on gelatine-coated glass coverslips was performed as described 
previously (13) using a primary antibody against tetra-His (Qiagen; 1:200) and an Alexa488-labeled 
secondary antibody (Invitrogen, Molecular Probes, Groningen, Holland; 1:200). 
 
Purification of the PAX3 DNA-binding domain protein 
The PAX3 part represented in the translocation product PAX3/FKHR (AA1-391 of PAX3) was HIS-tagged 
(NterPAX3His) and transiently expressed in 293T cells. 48 hours after transfection the cells were lysed in 
a buffer containing 50 mM NaH2PO4 (pH 8.0), 1% Triton X-100, 300 mM NaCl, 10 mM imidazole, 40 mM 
NaF, 10 mM β-glycerolphosphate, 1 mM Na3VO4, 1mM EGTA, and 1x complete protease inhibitor mix 
including 1 mM EDTA (Roche, Rotkreuz, Switzerland). After centrifugation of the extract at 10’000 g for 10 
min, the supernatant was incubated with 8 µl/ml 50% Ni-NTA agarose (Qiagen) for 2 hours at 4°C. The Ni-
NTA agarose was then washed 4 times with a buffer containing 50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, 
and 20 mM imidazole and 2 times with a similar washing buffer containing 50 mM imidazole. The protein 
was eluted with a similar buffer containing 250 mM imidazole. 
For some applications the protein was desalted using a C8 reversed-phase HPLC column (Brownlee 
Aquapore RP-300, 2.1 x 100 mm, PerkinElmer, Shelton, USA). 
 
2D-SDS-PAGE 
Isoelectric focusing was performed on an IPGphor electrophoresis unit (Amersham Pharmacia Biotech, 
Uppsala, Sweden) according to standard protocols (14). Immobiline IPG strips with a non linear pH 
gradient of 3-10 (Amersham) were used and the samples were applied on the strips by in-gel rehydration. 
SDS-PAGE was carried out on a Protean II xi system (Bio-Rad, Hercules, CA, USA) with 40 mA/gel at 
15°C. Gels consisted of 13 % w/v acrylamide with 2.7 % piperazine diacrylamide (PDA) as crosslinker. 
Proteins were visualized by a long silver nitrate staining.  
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Enzymatic digestion and LC-MALDI-TOF-MS analysis of the peptides 
The desalted protein solution was dried in a vacuum centrifuge and redissolved in a solution containing 
150 mM Tris, 6 M urea, and 6 mM EDTA (pH = 8). 10 µl were then incubated for 2 h at 37°C. 5 µl of a 
solution containing 0.5 µg of Lys C (Roche Diagnostics, Mannheim, Germany) and 45 µl H2O were added 
and incubated overnight at 37°C.  
Peptides were separated on a reversed-phase capillary HPLC column (PepMap C18, 0.3 x 150 mm, LC 
Packings, Amsterdam, Netherlands) and collected onto a 600 µm AnchorChipTM  target (Bruker Daltonics, 
Leipzig, Germany), using a Probot microfraction collector (LC Packings), in 15 s intervals. 1.5 µl of matrix 
solution was added to each fraction. A 1:10 dilution of saturated HCCA (α-cyano-4-hydroxycinnamic acid 
in 33 % CH3CN, 0.1 % TFA) in Ethanol/Aceton 2:1 was used as matrix solution. Mass mapping was 
performed with an autoflex® MALDI-TOF-MS (Bruker Daltonik). Phosphorylated peptides were analyzed in 
the linear positive-ion mode with delayed extraction (60 ns) and the following voltages were applied; 
source 20 kV, extraction 18.80 kV, lens 7.85 kV. 
 
Protein analysis with LC-ESI-MS 
Electrospray ionisation mass spectrometry (ESI-MS) was performed on a PE SCIEX API 365 LC-MS/MS 
system. Mass spectra were acquired in the mass range of m/z = 1000 to 3000 with step size 0.1 (scan 
time 6 sec). Chromatographic separation was performed on an Ultimate system (LC Packings) equipped 
with a Vydac C8 capillary column (0.3 x 150 mm). The flow rate was 4 µl/min. 
 
In vivo labeling with [32P]orthophosphate  
293T cells were transfected with NterPAX3His or empty vector. 36 hours post-transfection, cells were 
washed two times with phosphate-free MEM, and then incubated for 6 hours in phosphate-free MEM 
supplemented with 80 µCi/ml [32P]orthophosphate (Phosphorous-32; GE Healthcare, Amersham, 
Buckinghamshire, UK). Thereafter, NterPAX3His was purified with the help of Ni-NTA agarose. Purified 
proteins were Western blotted, followed by detection of 32P with a phosphorimager (Molecular Dynamics, 
Sunnyvale, CA, USA). 
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Transactivation assay 
PAX3/FKHR or PAX3 constructs together with a reporter plasmid containing the luciferase gene 
downstream of PAX3 paired- or homeodomain DNA-binding sites (6xCD19 DNA-binding sites (15) or P3 
binding site (16)) and a plasmid containing the lacZ gene was transfected into 293T or NIH3T3 cells or 
electroporated into Rh4 cells using the AMAXA system (Program O17, buffer R) in ratios ensuring 
measurement in the linear range of the assay. Similarly, a FKHR construct together with a reporter 
plasmid containing the luciferase gene downstream of the bim promoter (17) and a plasmid containing the 
lacZ gene was transfected into NIH3T3 cells. 
For measurement of effects of PKC412, cells were incubated 16 hours post-transfection with PKC412 or 
DMSO vehicle for 24h, followed by lysis in reporter lysis buffer (Promega, Madison, WI, USA). ß-
Galactosidase and luciferase activities were determined with the corresponding assay systems (Promega). 
Luciferase activity values were normalized with the ß-galactosidase activity values and values of empty 
vector controls were subtracted. 
 
Mutagenesis 
PAX3/FKHR mutants were generated using the “GeneTailor site-directed mutagenesis system” 
(Invitrogen) according to the manufacturer’s instructions. All constructs were sequenced for verification. 
 
Silencing of PAX3/FKHR 
Silencing of PAX3/FKHR by siRNA was performed as described previously (8).  
 
Real time PCR 
qRT-PCR was performed under universal cycling parameters on an ABI7900 instrument using 
commercially available target probes and Mastermix (all from Applied Biosystems, Applera Europe BV, 
Rotkreuz, Switzerland). Detection of PAX3/FKHR was achieved using PAX3 forward 
(5’GCACTGTACACCAAAGCACG3’) and FKHR reverse (5’AACTGTGATCCAGGGCTGTC3’) primers 
applying the fluorescent SYBR green method (Applied Biosystems). Cycle threshold (CT) values were 
normalized to GAPDH. Relative expression levels of the target genes among the different samples were 
calculated using the CT method. 
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CIP treatment of NterPAX3His 
12 µl of purified NterPAX3His or nuclear extracts of 293T cells overexpressing NterPAX3His were 
incubated with CIP buffer alone, 10U CIP (Promega), or 10U of CIP in presence of 60 mM EDTA and 4 
mM Na3VO4 as phosphatase inhibitors in a volume of 20 µl for 30 min at 37°C. Reactions without 
inhibitors were stopped by adding 60 mM EDTA and 4 mM Na3VO4.   
  
Electrophoretic mobility shift assay (EMSA) 
EMSA with biotinylated oligonucleotides containing a homeodomain 
(5`TGATTGCGGTGCTAATTGATTAACTTCGCATACCTGAT3`) or a paired domain 
(5`CTGGAGGGTTCCTGGAGAATGGGGCCTGAGGCGTGACCACCGCCTTCCTCTCTGGG3`) binding 
site was performed as described previously (15). EMSA reactions were resolved in 6% DNA retardation 
gels (Invitrogen) followed by blotting onto nylon membranes (Millipore, Billerica, MA, USA). Oligos were 
detected using the chemiluminescent nucleic acid detection module (Pierce, Rockford, IL, USA). 
 
RMS xenograft studies 
107 Rh4 or Rh30 cells were injected into the right flank of athymic CD1 nude (nu/nu) mice (Charles River, 
Germany). When tumors reached a volume of 130 - 200 mm3, oral treatment with PKC412 (100 
mg/kg/day) or placebo for 15 days was started. Tumor diameters (d1, d2) were measured 3 times a week 
using a digital calliper. Tumor volumes were calculated with the formula: V = (4/3) π r3, where r = ((d1 + 
d2)/4). At the end of the treatment period, tumors were isolated and fixed in 4 % paraformaldehyde in PBS. 
Cell proliferation was assessed by Ki-67 immunostainings (clone SP6; NeoMarkers, Fremont, USA). 
Furthermore, apoptosis was detected by TUNEL staining according to the manufacturer’s instructions (in 
situ cell death detection kit, Fluorescin, Roche, Rotkreuz, Switzerland). Ki-67 or TUNEL positive cells were 
scored in 10 randomly selected visual fields. 
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Results 
Treatment of RMS cells with kinase inhibitors 
Recent gene expression studies of RMS (18) identified a series of receptor tyrosine kinases (RTKs) with 
potential oncogenic capabilities highly expressed in RMS. Therefore, we tested a series of small molecule 
inhibitors targeting RTKs in comparison to the mTOR inhibitor rapamycin (19) for potential growth 
inhibitory effects on two aRMS (Rh4, Rh30) and two eRMS (RD, Ruch-2) cell lines, as assessed by MTT 
assay (Fig.1A). Induction of cell death by the different inhibitors was measured by trypan blue exclusion 
assays (Fig.1B).  
In accordance with previous studies (19), Rapamycin showed growth inhibitory effects for both aRMS and 
eRMS cells (Fig.1A). However, the effects for Rh4 and Ruch-2 cells were small and no clear dose-
response relationship was found within the tested concentration range. Furthermore, no significant loss of 
cell viability was observed (Fig.1B). 
PKI166 and CGP59326, known to block the activity of either both EGFR (ErbB1) and ErbB2, or only 
EGFR, respectively, affected neither cell growth nor viability (CGP59326) or inhibited cell growth, but 
without significant induction of cell death (PKI166) (Fig. 1A, B), suggesting inhibition of proliferation rather 
than induction of cell death in RMS cell lines.   
The c-met inhibitor NVP-ABG424-NX-4 influenced cell growth in all RMS cell lines moderately, except for 
RD cells (Fig. 1A), in which a dramatic induction of cell death was observed, suggesting that strong 
sensitivity to this drug was observed in one cell line only.  
Finally, PKC412 inhibited proliferation of the aRMS cells Rh4 and Rh30 much more effectively than RD 
and RUCH-2 cells (Fig. 1A). In addition, cell death was significantly induced only in aRMS and not in 
eRMS cells (Fig. 1B).  
Taken together, among the inhibitors tested, PKC412 demonstrated the most efficient and specific anti-
proliferative effect for aRMS cells. Therefore, PKC412 was further characterized. 
Therapeutically significant IC50 levels for PKC412 were only achieved in aRMS cells (Fig.2A). To 
investigate whether cell death is due to apoptosis, we used an activated caspase-3 assay. As shown in 
Fig. 2B, induction of caspase-3-dependent apoptosis dramatically increased in aRMS cells when treated 
with 0.5 µM PKC412 for 24-72 hours. In contrast, apoptosis was only marginally enhanced in eRMS cells. 
This finding was confirmed by examining the caspase-3 substrate PARP (Fig.2C), which was cleaved as 
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early as 4 hours after incubation with 0.5 µM PKC (Fig. 2B). Therefore, PKC412 selectively induces 
caspase-3 dependent apoptosis in alveolar but not in embryonal RMS cells. 
 
PKC412 influences the transcriptional activity of PAX3/FKHR 
ARMS cells are known to undergo apoptosis upon silencing of PAX3/FKHR by oligonucleotides (7) or 
siRNA (8).  
Hence, we hypothesized that PKC412 might influence PAX3/FKHR activity. In the absence of PKC412, 
ectopic expression of PAX3/FKHR in 293T cells induces transcription of CB1, as detected by qRT-PCR 
(Fig.3A). A mutation (N269A) within the homeodomain of PAX3, specifically inactivating its homeodomain-
DNA binding (16), prevents induction of CB1 transcription (Fig.3A), but not of the paired domain-
dependent target gene AP2β (data not shown and (8)). This strongly suggests that activation of CB1-
transcription in 293T cells is depending on PAX3/FKHR activity, confirming results of earlier studies (20). 
Furthermore, specific silencing of PAX3/FKHR by siRNA in Rh4 cells reduced CB1 expression to less than 
20 percent compared to control (Fig.3A). The transcriptional level of CB1 was therefore used to monitor 
PAX3/FKHR activity in further experiments.  
Surprisingly, in presence of PKC412, PAX3/FKHR-induced transcription of CB1 in 293T cells as well as 
endogenous mRNA levels in Rh4 cells were inhibited (Fig.3B). This inhibitory effect of PKC412 was 
validated by transactivation assays using luciferase reporter plasmids containing specific promoters for the 
paired- (6xCD19) or the homeo- (P3) domain of PAX3. In these assays PKC412 strongly reduced 
PAX3/FKHR induced expression of the reporter in both 293T cells and Rh4 cells (Fig.3B).  
To exclude that PKC412 mediates these effects via downregulation of PAX3/FKHR expression, mRNA 
and protein levels were measured in transfected 293T and Rh4 cells. Surprisingly, PKC412 incubation led 
to an increase of PAX3/FKHR on the mRNA as well as on the protein level in 293T cells, whereas in Rh4 
cells PAX3/FKHR levels were only slightly influenced (Fig.3C). Taken together, these results suggest that 
PKC412 modulates the transcriptional activity of PAX3/FKHR. 
To evaluate which part of the fusion protein is target of this PKC412 effect, we measured its influence on 
the activity of the translocation product PAX3/NCOA1 (18) and on PAX3 and FKHR alone. This approach 
demonstrated that PKC412 inhibited induction of CB1 by PAX3/NCOA1 as well as the transactivation 
activity of PAX3 very similar to PAX3/FKHR (Fig.3D). In contrast, the transactivation potency of FKHR on 
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a luciferase reporter driven by the promoter of the FKHR-target gene bim (17) was unchanged by PKC412 
(Fig.3D). Taken together, these data suggest that it is the PAX3 rather than the FKHR domain of the 
fusion protein that is influenced by PKC412.  
 
The PAX3 domain of PAX3/FKHR is phosphorylated at multiple sites  
We hypothesized that the kinase inhibitor PKC412 might affect potential phosphorylation sites within the 
PAX3 domain as a mechanism to reduce activity. We therefore searched for phosphorylations within this 
domain directly using a His-tagged form (NterPAX3His). Immunofluorescence of transfected 293T cells 
with an anti-His-tag antibody confirmed that NterPAX3His was localized in the nucleus, as known for full 
length PAX3/FKHR (Fig.4A), which was not changed after incubation with 10 µM PKC412 for 24h. 
NterPAX3His was then purified from 32P-labeled 293T cells and tested for potential phosphorylation. As 
demonstrated in Fig.4B, a strong 32P-signal was detected in the NterPAX3His protein, demonstrating that 
PAX3 is indeed a phosphoprotein. Analysis with 2D-gel electrophoresis further supported this conclusion, 
as the purified PAX3-His protein appeared as mixture of several species with different pIs, reminiscent of 
multiple phosphorylation sites in the protein (Fig.4B). Treatment of purified NterPAX3His protein or nuclear 
extracts from 293T cells overexpressing NterPAX3His with CIP reduced the ability of NterPAX3His to bind 
to oligonucleotides containing a homeo- or a paired-domain specific binding site (Fig.4C), suggesting that 
phosphorylation influences DNA binding properties of PAX3. 
LC-MALDI-TOF mass spectrometric analysis of LysC-digested PAX3-His protein revealed 4 (or probably 
5) phosphates in the peptide 186-216 (Fig.4D). This peptide contains six Ser residues (S187, S193, S197, 
S201, S205, S209) as potential phosphorylation sites (Fig. 4D). Four out of these six Ser are conserved 
among the PAX3 proteins from different species suggesting irreplaceability for proper function of PAX3 
(Fig.4D). Interestingly, in silico analysis using different web resources revealed that these six Ser residues 
and the two flanking S180 and S222 have the highest probability for being phosphorylated in PAX3 (data 
not shown). 
 
Phosphorylation influences activity of PAX3/FKHR 
To test directly whether PKC412 influences the phosphorylation status of NterPAX3His, protein purified 
from PKC412- and control-treated 293T cells was analyzed by 2D-gel electrophoresis. As shown in Fig. 
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5A, PKC412 induced a clear shift towards more basic pIs. Furthermore, electrospray ionization (Fig.5A) as 
well as MALDI-TOF (data not shown) mass spectrometric analysis of the same proteins revealed a 
PKC412-treatment-induced shift towards smaller protein species. These results suggest that PKC412 
affects the post-translational modification of PAX3.  
To test whether phosphorylation directly affects PAX3/FKHR activity, we mutated the six Ser individually 
into Asp, to mimic phosphorylation. However, these single mutations did not affect sensitivity of 
PAX3/FKHR towards PKC412 (data not shown). Instead, mutation of all six Ser together into Asp 
(PAX3/FKHR 6xD) rescued, at least partially, transcriptional activity of PAX3/FKHR (Fig.5B, left panel). As 
expressed protein levels of wt and mutated protein were similar (Fig.5B, right panel), this suggests 
involvement of more than one of these sites in regulation of PAX3/FKHR activity. Additional mutation of 
S180 into Asp (PAX3/FKHR 7xD) did not lead to a significant further increase in rescue (Fig.5B), whereas 
mutation of S222 led to complete loss of transactivation activity (data not shown). In accordance with the 
behaviour of the Asp mutants, also single loss-of-function mutations of the six Ser into Ala did not affect 
transactivation potencies (data not shown), whereas multiple mutations decreased transactivation activity 
as measured in transactivation assays using the 6xCD19 reporter plasmid up to about 50% (Fig.5C).  
To test whether these phosphorylation sites are involved in regulation of PAX3 DNA-binding, we treated 
nuclear extracts of 293T cells transfected with wildtype NterPAX3His or NterPAX3His 7xD with CIP. 
EMSA experiments demonstrated that in contrast to wildtype NterPAX3His, DNA-binding of the mutant 
NterPAX3His 7xD to both paired- or homeodomain specific oligos was not influenced by CIP treatment 
(Fig.5D, left panel). This suggests that indeed phosphorylation influences DNA binding of NterPAX3His. 
To test whether also PKC412 affects DNA-binding of PAX3/FKHR, EMSA was performed with nuclear 
extracts from PAX3/FKHR-transfected cells incubated with or without 10 µM PKC412. As shown in Fig.5D 
(right panel), PKC412 treatment indeed decreases DNA-binding of PAX3/FKHR. 
Taken together, we conclude that specific phosphorylation positively influences DNA binding of PAX3 
thereby modulating PAX3(/FKHR) activity, which in turn can be influenced by PKC412 treatment. 
 
Inhibition of in vivo tumor growth of aRMS xenografts by PKC412 
As kinase inhibitors are interesting molecules for potential treatment of aRMS, we further investigated the 
effects of PKC412 on tumor growth in vivo. Towards this end, Rh4 and Rh30 xenograft mice were treated 
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daily by oral administration of PKC412 (100 mg kg-1) for 15 days. In both xenograft models tumor growth 
was significantly inhibited by PKC412 (Fig. 6A). In Rh4 xenografts a complete suppression of tumor 
growth was observed, whereas in Rh30 xenografts tumor growth was strongly decreased. 
To further characterize the effect of PKC412 on xenografts, the tumors were isolated and characterised. 
Tumor morphology was determined by H&E stainings. Placebo-treated Rh4 and Rh30 xenograft sections 
(Fig. 6C, upper row) both showed a high density of actively growing tumor cells. In contrast, PKC412 
treated tumors showed either a dramatic increase in extracellular material (Rh4 xenografts, Fig. 6C, lower 
left panels) and/or necrotic areas (Rh30 xenografts, Fig.6C, lower right panels).  
In order to quantify the influence of PKC412 on tumor cell proliferation in vivo, tumor sections were 
immunohistochemically stained for the proliferation marker Ki-67 and apoptotic cells were detected by 
TUNEL staining. As shown in Fig. 6B, the number of Ki-67 positive cells was decreased in both Rh4 and 
Rh30 xenografts after treatment, whereas the number of apoptotic tumor cells was dramatically increased 
by 4 - 5 fold in tumors isolated from both Rh4 and Rh30 xenograft mice treated with PKC412. 
In summary, PKC412 significantly inhibited tumor growth, reduced numbers of actively dividing tumor cells 
while simultaneously increasing number of apoptotic cells in vivo. 
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Discussion 
For RMS, the current treatment is still based on conventional treatment regimens (surgery, chemotherapy 
and radiotherapy), which in the case of metastasized aRMS often fail. Alternative treatment agents are 
therefore highly desired.  
In an approach to find targetable pathways in RMS, we analyzed recent gene expression data of RMS 
biopsies (18) for the expression of kinases with a known tumor-relation and tested a series of kinase 
inhibitors against three selected kinases (EGFR, HGFR, FGFR), in comparison to mTOR which has been 
characterized as target in RMS in vitro (19), for their ability to specifically reduce the growth of different 
aRMS and eRMS cell lines.  
From all substances tested, PKC412 was found to have the most promising anti-growth effect with 
specificity against the aRMS subgroup. This compound induces very efficient apoptosis in submicromolar 
concentrations, which is well below the steady-state plasma levels of 2-7 µM, which were achieved in 
phase I clinical trials with this substance (21). As these concentrations were well tolerated by patients, our 
in vitro data provide a first preclinical rationale for clinical studies of aRMS treatment.  
PKC412 is a derivative of staurosporine and was developed as PKC inhibitor. Although being more 
specific when compared to staurosporine, which is known to bind to a bulk of the whole kinome (22), 
PKC412 was found to inhibit a wide range of kinases such as cdk1/cycB, PKA, c-src, KDR (VEGFR2) and 
others in submicromolar concentrations (23). Based on these characteristics, PKC412 has been 
successfully applied as inhibitor of different oncogenic kinases in a range of tumors in vitro, e.g. as FGFR 
inhibitor in myeloproliferative disorder or multiple myeloma (24, 25), as kit inhibitor in mast cell leukemia 
(26) or as Akt inhibitor in myeloma (27). Its potential clinical use is most advanced as Flt3 inhibitor for the 
treatment of AML, for which PKC412 is used in a phase II clinical study (11).  
Mechanistically, we found an unexpected inhibitory effect of PKC412 on transcriptional activity of 
PAX3/FKHR, an important potential therapeutic target in RMS. This effect is based on several 
observations: induction of target gene transcription upon ectopic expression in the non-RMS cell line 293T 
can be inhibited. Also, in the aRMS cell line Rh4, the endogenous transcription of these target genes is 
affected by PKC412, albeit less pronounced. However, while 293T cells do tolerate even 10 µM PKC412, 
aRMS cells rapidly undergo apoptosis upon PKC412 treatment, thereby interfering with determination of 
target gene levels. In contrast, when using reporter-plasmid based transactivation systems to measure 
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PAX3/FKHR activity, the effects of PKC412 in both 293T and Rh4 cells were comparable, suggesting 
effective inhibition of PAX3/FKHR activity by PKC412 also in Rh4 cells.  
We found that the inhibitory effect of PKC412 on PAX3/FKHR activity is, at least partially, based on 
modulation of phosphorylation sites in the PAX3 part of the fusion protein. Nevertheless, it can not be 
excluded that also other sites are influenced by PKC412. While phosphorylation of PAX2 (28), PAX6 (29) 
and PAX8 (30) has been reported, phosphorylation sites in PAX3 have not been identified so far. 
However, an influence of PKC on the transcriptional activity of PAX3 in presomitic mesoderm has been 
suggested in recent work (31). Supporting this observation, we found that PKC412 can inhibit activity of 
PAX3 in a similar manner to PAX3/FKHR. The region encompassing phosphorylation sites in 
NterPAX3His described here (peptide 186-216) is located in the linker region between the two DNA 
binding domains of PAX3.  
Generally, phosphorylation events can regulate the activity of transcription factors via several different 
mechanisms involving changes in subcellular localization, protein stability, DNA binding activity, and 
protein-protein interactions. As PKC412 did not influence the nuclear localization of NterPAX3His and 
even increased the expression level of PAX3/FKHR in 293T cells, we exclude the first two mechanisms as 
relevant. However, we could demonstrate that phosphorylation of the linker region influences PAX3 DNA 
binding via both the paired- and the homeodomain. This is in accordance with earlier findings 
demonstrating a influence of this region on the DNA binding of PAX3 (32).  
MALDI-TOF analysis revealed that at least 4 out of 6 Ser residues are phosphorylated in the peptide 186-
216 of NterPAX3His. Interestingly, only multiple but not single mutations of these sites into Asp reduced 
the sensitivity of the protein towards PKC412, suggesting that a combination of several phosphorylated 
sites is necessary for full transcriptional activity of PAX3/FKHR. Whether all or a combination of some of 
these sites is involved in PKC412-sensitivity is under current investigation. Furthermore, the fact that 
exchange of all the six Ser by Asp did not completely protect from PKC412-mediated inhibition of 
PAX3/FKHR suggests that, besides modulation of these phosphorylation sites, other mechanisms 
regulating PAX3/FKHR activity might be affected by PKC412. 
Translocation-positive aRMS cells have been shown to highly depend on the presence of active fusion 
proteins, as silencing of PAX3/FKHR by oligonucleotides (7) or siRNA (8) very efficiently induces 
apoptosis in these cells. This suggests that reduction of PAX3/FKHR activity by PKC412 in aRMS cells 
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may be, at least in part, the responsible mechanism for induction of apoptosis. However, taking into 
account its broad inhibitory spectrum, it can not be excluded that some of its proapoptotic effects in aRMS 
cells are based on other mechanisms. As tumors have many, and often overlapping, biological pathways 
they can use to grow and resist death, inhibition of different signal transduction pathways in parallel may 
be even more effective when compared to therapies targeting specifically one single pathway (for review 
see (33)). Hence, inhibition of multiple signaling pathways by PKC412 could be of clinical advantage. 
Furthermore, such multitargeted therapy is thought to have an increased likelihood of sustained 
effectiveness due to the reduced probability for appearance of resistant clones.  
About one third of the known cellular oncogenes are transcription factors (34) (3), therefore these factors 
are highly interesting targets for potential therapeutic interventions. Unfortunately, the absence of a 
directly targetable enzymatic activity complicates targeting of these factors. Experimental approaches to 
inhibit transcription factors, such as antisense nucleic acid approaches, have been shown to be very 
useful in vitro, also in the case of aRMS (7), but the technical complexity of an application in vivo prevents 
routine clinical implementation for the moment. As demonstrated in our study, the use of small molecule 
kinase inhibitors influencing transcription factor activity could be an alternative. As most of the 
approximate 1000 human transcription factors are thought to be regulated by phosphorylation (35), the 
principles shown here may be worthwhile to explore for additional tumors addicted to oncogenic 
transcription factors, e.g. Ewing’s sarcoma. 
In summary, our data reveal a novel mechanism regulating PAX3/FKHR activity and at the same time 
suggest PKC412 as an interesting potential agent for the treatment of aRMS providing a preclinical 
rationale for clinical studies with this inhibitor in aRMS patients. 
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Figure Legends 
 
Fig.1. Screening of small molecule inhibitors for growth inhibitory effects on aRMS (Rh4, Rh30) and eRMS 
(RD, Ruch-2) cell lines. A, Changes in proliferative activity as measured by MTT assays. Inhibitors were 
applied for 96 hours at three concentrations (indicated in µM). Columns, mean of three independent 
experiments performed each in triplicate; bars, SD. B, Cell death was assessed using trypan blue 
exclusion. Cells were treated with the median concentration of the inhibitors described in (A) for 96 hours. 
Columns, mean of three independent experiments; bars, SD.  
 
Fig.2. PKC412 induces apoptosis in aRMS but not in eRMS cell lines. A, IC50 values of PKC412 as 
determined by MTT assays of RMS cells treated with increasing concentrations of PKC412 (0 - 10 µM) for 
96 hours. Note: the IC50 value for RD cells was not determinable (n. d.) because a 50 % inhibition of 
proliferative activity could not be achieved. Columns, mean of three independent experiments performed 
in triplicate; bars, SD.  B, Identification of apoptotic cells by an activated caspase-3 assay after treatment 
with 0.5 µM PKC412 (X) or DMSO (◊) for 24 – 72 hours. Mean of three independent experiments; bars, 
SD. Corresponding phase contrast and fluorescence images display total and apoptotic cells after 72 
hours, respectively. C, Western blot analysis of PARP cleavage in RMS cells after treatment with 0.5 µM 
PKC412 or DMSO for 2, 4, 8 and 16 hours.   
 
Fig.3. PKC412 inhibits the transcriptional activity of PAX3/FKHR and PAX3. A, Left upper panel, Induction 
of transcription of the PAX3/FKHR target gene CB1 in 293T cells upon ectopic expression of the indicated 
PAX3/FKHR constructs as measured by qRT-PCR. Results of one representative experiment are shown. 
Left lower panel, Levels of PAX3/FKHR wt and mutant protein in 293T cells transfected with the indicated 
amount of PAX3/FKHR plasmid as detected by Western blot with an anti-FKHR antibody. Right upper 
panel, Effect of siRNA-mediated silencing of PAX3/FKHR on the transcription level of CB1 in Rh4 cells as 
measured by qRT-PCR at the indicated time points. CB1 mRNA levels were normalized with GAPDH 
levels. Right lower panel, Levels of PAX3/FKHR protein in Rh4 cells upon treatment with anti-PAX3 (si) or 
scrambled (sc) siRNA for the indicated time periods. B, Left panel, Effect of PKC412 on ectopic 
PAX3/FKHR-induced CB1 transcription in 293T cells and on endogenous CB1 transcription in Rh4 cells 
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as measured by qRT-PCR. Cells were incubated with the indicated concentration of PKC412 for 16h. 
Mean and SD of three independent experiments are shown. Right panel, Relative luciferase levels after 
transfection of PAX3/FKHR and reporters with specific promoters for the paired- (6xCD19) or the homeo- 
domain (P3). Rh4 or 293T cells transfected with PAX3/FKHR were incubated with 10 µM of PKC412 for 
16h. Mean and SD of three independent experiments are shown. C, Left panel, PAX3/FKHR mRNA levels 
in transfected 293T and Rh4 cells measured by qRT-PCR. Cells were treated as described in B. Right 
panels, PAX3/FKHR protein levels in transfected 293T cells (upper panel) or Rh4 cells (lower panel) 
measured by Western blot detection with an anti-FKHR antibody. Cells were treated as described in B. D, 
Left panel, Transcriptional activation of CB1 by PAX3/FKHR and PAX3/NCOA1. 293T cells were 
transfected with the indicated PAX3-fusion protein construct and incubated with 10 µM PKC412 for 16h. 
Right panel, Transactivation potency of PAX3, PAX3/FKHR and FKHR. NIH3T3 cells transfected with 
PAX3 or PAX3/FKHR together with the 6xCD19 reporter plasmid or FKHR together with the bim reporter 
plasmid were incubated with the indicated concentrations of PKC412 for 16h before measurement of 
reporter expression. Mean and SD of three independent experiments are shown. 
 
Fig.4. The PAX3 part of PAX3/FKHR is phosphorylated in vivo. A, Immunofluorescent detection of 
NterPAX3His with an α-tetra-His antibody in transfected 293T cells cultivated in presence or absence of 
10 µM PKC412 for 24h. B, Upper panels, Phosphoimager detection of 32P (left) and α-tetra-His 
immunodetection (right) of Western blotted NterPAX3His protein purified from 32P labeled 293T cells 
ectopically expressing NterPAX3His (right lanes). Mock transfected cells were processed as control (left 
lanes).  Lower panels, Silver stained 2D-gel of NterPAX3His protein purified from 293T cells (upper part) 
and α−tetra-His immunodetection of a blotted 2D gel of the same protein (lower part). C, EMSA of purified 
NterPAX3His protein (lanes 1-3) and nuclear extract of control (lane 4) or NterPAX3His-transfected 293T 
cells (lanes 5-10) with oligos containing a homeodomain (lanes 1-7) or a paired domain (lanes 8-10) 
binding site. Protein samples used for EMSA were preincubated with CIP buffer alone (lanes 1,5,8), CIP 
(lanes 2,6,9) or CIP in presence of phosphatase inhibitors (lanes 3,7,10), respectively. D, Upper left panel, 
MALDI-TOF mass spectrum of the peptide aa186-216 of PAX3. NterPAX3His was purified from 
NterPAX3His-transfected 293T cells and digested by LysC. Resulting peptides were isolated by 
chromatography and investigated for phosphorylation by MALDI-TOF-MS. 2P, 3P, 4P assign peaks of the 
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2, 3 and 4 fold phosphorylated peptide, respectively. Upper right panel, Schematic representation of the 
domain structure of PAX3 depicting the localization of the identified phosphorylation sites in PAX3. Bottom 
panel, Alignment of the PAX3 protein sequences from the indicated species in the region with identified 
phosphorylation sites. Potential phosphorylation sites conserved among all four species (S187, S201, 
S205, S209) are indicated by arrows. 
 
Fig.5. PKC412 influences phosphorylation of PAX3/FKHR. A, Upper panels, Silver stained 2D-gel of 
NterPAX3His protein purified from transfected 293T cells untreated (upper panel) or treated with 10 µM 
PKC412 (lower panel) for 16h. Lower panels, ESI-MS analysis of the same proteins as in A. B, Left panel, 
Effect of PKC412 on induction of CB1 transcription in 293T cells upon ectopic expression of wildtype or 
mutant PAX3/FKHR as measured by qRT-PCR. Mean and SD of three independent experiments are 
shown. Right panel, Expression levels of the indicated PAX3/FKHR forms upon transfection into 293T 
cells. C, Relative transactivation potencies of wildtype PAX3/FKHR or PAX3/FKHR with the indicated Ser-
Ala mutations on the 6xCD19 reporter plasmid as measured by luciferase assays. Mean and SD of three 
independent experiments are shown. *, P<0.05 compared to wt. D, Left panel, EMSA with nuclear extracts 
of 293T cells transfected with NterPAX3His wt (lanes 1-3, 8-10) or with NterPAX3His 7xD (lanes 4-6,11-
13) and of untransfected cells (lanes 7,14). Nuclear extracts were either incubated with CIP buffer alone 
(lanes 1,4,8,11), treated with CIP (lanes 2,5,9,12) or treated with CIP in presence of phosphatase 
inhibitors (lanes 3,6,10,13). EMSAs were performed with homeodomain (P2) or paired domain (CD19) 
specific oligos. Right upper panel, EMSA with nuclear extracts from untransfected (left lane) or 
PAX3/FKHR-transfected 293T cells (right four lanes) and the homeodomain specific oligo. Cells were 
incubated with 10 µM PKC412 or vehicle alone for 1 and 2 hours as indicated. Right lower panel, 
expression levels of PAX3/FKHR in the nuclear extracts used for EMSA as detected by an anti-FKHR 
antibody. 
 
Fig.6. In vivo anti-tumor effects of PKC412 in two different aRMS xenograft models. A, Growth inhibition of 
Rh4 and Rh30 xenografts in female CD-1 athymic nude mice (nu/nu) treated with a daily dose of 100 
mg/kg PKC412 for up to 15 days. B, Evaluation of proliferation and apoptosis in PKC412-treated 
xenografts by immunohistochemistry and TUNEL staining. Tumor sections were stained for Ki-67 (upper 
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row) or TUNEL-stained (lower row). Proliferation and apoptosis were quantified by counting Ki-67- and 
TUNEL-positive cells. Columns, means for each treatment group (n = 3 - 6); bars, SD. C, Haematoxylin 
and eosin (H&E) stainings of Rh4 (A - D) and Rh30 (E - H) xenograft sections. Upper row, placebo-treated 
tumors; lower row, PKC412-treated tumors. Cells within the square in left panels are shown in right panels 
at higher magnification (Bar 200 µm (left panels) and 100 µm (right panels)). 
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